Institute for Systems Biology and AB SCIEX Partner
News Feb 08, 2013
Medical care is expected to become more personalized and better able to help prevent the onset of diseases in the future, thanks to groundbreaking research into P4 medicine underway by world-renowned scientists at the Institute for Systems Biology, including National Medal of Science award winner Leroy Hood, MD, PhD., and ISB proteomics research director, Robert Moritz, PhD., and now supported by a new collaboration with AB SCIEX.
ISB and AB SCIEX have signed a multi-year agreement to collaborate on the development of methods and technology in proteomics mass spectrometry with the goal to redefine biomarker research and complement genomics through fully comprehensive quantitative proteomics analysis. This will help advance the development of a new approach to medical care.
ISB’s concept of P4 medicine promises to provide deep insight into disease mechanisms on the path to develop medical care that is predictive, personalized, preventive and participatory (the four “P”s) – a pioneering vision that requires a combination of analytical tools, workflows, databases, collaborations and computational strategies.
“With breakthroughs in translating research into clinical relevance, P4 medicine is expected to enable the creation of a virtual cloud of billions of data points around each individual as the basis for straightforward predictions about health and disease,” said Dr. Hood, ISB president and co-founder. In December, he was named a recipient of the National Medal of Science, which is the highest honor the President of the United States can bestow on a scientist, in recognition of visionary work for the advancement of science.
Led by Dr. Hood, ISB’s groundbreaking research is being accelerated by SWATH™ Acquisition, a data-independent acquisition (DIA) mass spectrometry workflow that can quantify virtually all detectable peptides and proteins in a complex sample – all in a single analysis.
“Quantifying enormous numbers of protein analytes at the same time is a critical need to accelerate P4 medicine and the democratization of proteomics, a revolution that is akin to the sequencing of the genome and the democratization of DNA,” added Dr. Hood. “SWATH is a game-changing technique that essentially acts as a protein microarray and is the most reproducible way to generate comprehensive quantitation of the entire proteome. It generates a digital record of the entire proteome that can be mined retrospectively for years to come.”
ISB’s know-how in systems biology and informatics will support the development of SWATH libraries, similar to its highly regarded SRMAtlas project for the human proteome, pioneered by Rob Moritz and his collaborators, and the proteomes of other clinically-relevant organisms. “With complete proteome-wide libraries, ISB provides the basis to support comprehensive SWATH analysis,” said Dr. Moritz, ISB Proteomics Research Director.
Committed to an open policy of sharing data and methods, ISB will make the SWATH libraries available to the global scientific community to accelerate the use of SWATH for other biological research. Utilizing the depth in proteomics technology development and underpinned by the extensive proteomics computational resources in data interpretation tools, standards initiatives and database development under the leadership of Dr. Moritz, ISB will develop new SWATH technologies and tools to enable the community to quickly adopt comprehensive quantitative proteome analysis.
“Having the proteomics data standardized across laboratories and across samples really enables us to quantitate entire proteomes at a level that hasn’t been done before,” said Dr. Moritz. “We aim to define markers that can predict whether a patient will respond to a certain treatment or not, and applying SWATH will play a big part in taking our advancements to another level. Not only can we now complement the breadth of genomics, but we will have the much-needed libraries and software development going forward to make data-sharing quite easier and standardized.”
As a trusted partner with academic researchers, AB SCIEX has formed this strategic alliance with Dr. Hood, Dr. Moritz and their distinguished ISB colleagues through the AB SCIEX Academic Partnership Program to help broaden the availability of new technologies to researchers delving into omics research around the world.
“What ISB does with SWATH will set a new benchmark in proteomics research,” said Rainer Blair, President of AB SCIEX. “Our collaboration with ISB will help drive SWATH into the mainstream of analytical science and make comprehensive, reproducible and simplified omics data more accessible to biologists around the world.”
ISB will be using the AB SCIEX TripleTOF® 5600+ System and an Eksigent ekspert™ nano-LC 400 System as the instrument platforms on which to conduct the protein identification and quantitation. The TripleTOF 5600+ System provides the high speed necessary for SWATH Acquisition. TripleTOF technology combines high speed and high sensitivity with high resolution and accurate mass. ISB also plans to use SelexION™ technology, a recent advancement in differential ion mobility, in the future to advance its research.
All in a Droplet: Atomic Resolution of ALS Protein ResolvedNews
Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.READ MORE